Literature DB >> 29875963

Medication adherence and factors associated with poor adherence among type 2 diabetes mellitus patients on follow-up at Kenyatta National Hospital, Kenya.

Gabriel Waari1, Joseph Mutai2, Joseph Gikunju3.   

Abstract

INTRODUCTION: Medication non-adherence is a common problem facing health care providers treating adult type 2 diabetes mellitus patients. Poor glycaemic control associated with increased morbidity and mortality are resulting consequences. The objective of this study was to assess medication adherence among Type 2 diabetes mellitus patients.
METHODS: This is a cross-sectional study conducted at Kenyatta National Hospital from November 2015 to January 2016. 290 Type 2 diabetic patients were enrolled. A questionnaire was used for data collection. Adherence levels were determined by patient scores on Morisky Medication Adherence Scale-8 and glycaemic control by blood assay for glycosylated haemoglobin. Ordinal logistic regression modelling was done using STATA software to determine factors associated with poor medication adherence.
RESULTS: The prevalence of medication adherence low for 28.3 % [95% CI: 23.1, 33.5], medium for 26.2% (95% CI: 21.1, 31.3) and high for 45.5% (95% CI: 39.6, 51.3) of study participants. Glycaemic control was good (HbA1c < 7%) for 107 (36.9 %) of study participants. Dissatisfaction with family members support (OR = 2.99, CI = 1.12-7.98), patients with 2-10 years duration of disease (OR = 2.07, CI = 1.01-4.22), ever being admitted for diabetes mellitus (OR = 2.94, CI = 1.60-5.41), challenge in drug access (OR = 1.76, CI = 1.01-3.05) and dissatisfaction with attending clinicians (OR = 3.58, CI= 1.36 - 9.43) were factors found associated with poor medication adherence.
CONCLUSION: A majority of type 2 diabetes mellitus patients have suboptimal medication adherence. Family support, affordability of medications and good healthcare provider-patient communication are important in ensuring medication adherence.

Entities:  

Keywords:  Medication adherence; glycaemic control; type 2 diabetes

Mesh:

Substances:

Year:  2018        PMID: 29875963      PMCID: PMC5987072          DOI: 10.11604/pamj.2018.29.82.12639

Source DB:  PubMed          Journal:  Pan Afr Med J


Introduction

Poor and inadequate glycaemic control among the patients with Type 2 diabetes mellitus (DM) constitutes a major public health problem and accelerates the development of diabetes compli-cations [1, 2]. In 2003, the World Health Organization (WHO) launched a landmark report which clearly defined “adherence” as the extent to which a person's behavior including taking medication corresponded to agreed recommendations from a health care provider. Secondly it recognized suboptimal medication adherence as a major factor leading to poor glycemic control among diabetic patients [3]. A variety of studies have continued to show that patients who fail to adhere to the prescribed clinical regimens have poorer outcomes including higher rates of complications [4,5]. Various models have been postulated to help understand barriers towards medication adherence [3, 6, 7]. All these models have common elements of factors that relate to the patient including socio-economic characteristics, factors that relate to the disease stage and treatment and factors that relate to the health system including clinician communication. Currently in sub-Saharan Africa, the International Diabetes Federation (IDF) estimates that there are about 14.2 million people living with diabetes; it is projected that in 2040 this number will increase to 34.2 million people [8]. In Kenya, the prevalence of DM was 3.3% in 2007 and is projected to get to 4.5% in 2025 [9]. The prevalence in some urban areas has been estimated to be up to 10% [10]. Chronic complications occur in significant proportions among Kenyan patients with both early and long-standing Type 2 DM and these are related to poor glycaemic control [11, 12]. However, the status of Type 2 DM patients' adherence to anti diabetic therapy and the factors associated with poor adherence to diabetic medication are yet to be adequately studied in Kenya. This study thus estimates the magnitude of medication adherence and secondly identifies some factors that are associated with poor adherence to medication among typical Kenyan Type 2 DM patients. This information will assist individuals with diabetes and their health care providers plan appropriate interventions to ensure optimal health outcomes.

Methods

This was a cross-sectional study and was conducted from November 2015 and January 2016, at Kenyatta National Hospital. This is the largest public referral and teaching hospital in Kenya. The study population comprised of Type 2 diabetes mellitus patients (males and females) enrolled at the diabetes clinic and on oral or injection medication or both. The study participants had to be over 18 years and enrolled at the clinic for at least one month. Patients excluded for the study were patients attending their first visit, those aged below 18 years, Type 1 diabetes mellitus patients and those who were seriously ill or unable to speak. Sample size was determined using single proportion formula [13] considering a 95% confidence level, 5% margin of error and a known prevalence of adherence to diabetic medication among Type 2 diabetes mellitus patients of 25% [14]. This resulted in a calculated sample size of 289 patients. Study participants were selected using a systematic sampling procedure. On each day of the study, the first participant was determined by writing down the names of the first two patients in separate papers and thereafter choosing one randomly. Thereafter, every other patient that meets the selection criteria was enrolled into the study. Data collection: A structured questionnaire was used to gather information regarding socio-demographic characteristics. The participant's clinic file was reviewed to obtain information regarding the medication regimen and known co-morbid/complication states. Evaluation of medication adherence was done using the Morisky Medication Adherence Scale-8 (MMAS-8) [15-17]. A score of 8 indicates high adherence, a score of 6-7 indicates medium adherence whilst a score of less than 6 indicates poor adherence. Alcoholism screening was done using the CAGE test [18]. Item responses on the four-item CAGE test are scored 0 or 1; with a higher score an indication of alcohol problems. The study participants had two anthropometric measurements taken. Height was be measured without shoes to the nearest of 0.1 centimeter (cm) using a stand-meter. Weight was measured to the nearest of 0.1 kg on a hospital scale, with the participant wearing one-layer of clothes and with no shoes. Body Mass Index (BMI) was calculated as weight (kg) divided by the square of the height (m2). The cut-offs for BMI were be based on the WHO criteria, where underweight is defined as BMI < 18.5 kg/m2, normal weight as BMI between 18.5 kg/m2 and 24.99 kg/m2, over weight is defined as a BMI ≥ 25 kg/m2 and obesity is defined as a BMI ≥ 30 kg/m2 [19]. Finger pin-prick blood assay of glycosylated hemoglobin (HbA1C) was also done using the A1cNow® (PTS Diagnostics, IN, USA) point of care system. Data analysis: Analysis of the collected data was performed using STATA version 11.0 statistical software. Descriptive statistics such means, proportions and frequencies were used to express participants socio-demographic, clinical and anthropometric characteristics. Medication adherence prevalence was determined by proportion of patients who obtain a score of 8 on the Morisky Medication Adherence Scale. HbA1C values determined by blood assay were categorized to either good control for patients whose values were less than 7% and poor control for patients whose values were 7% or more. Alcoholism screening was done using the CAGE test [18]. A total score of 2 or greater was considered clinically significant. Chi-square test analysis was carried out to determine the statistical significance of the association between the MMAS-8 medication adherence categories and glycemic control categories and secondly between suboptimal adherence and the different independent categorical variables. All independent variables whose p-values did not exceed 0.2 were selected for inclusion in the multivariate analysis model. Collinearity was assessed and for variables that were identified to be collinear (r ≥=0.5, using Pearson's correlation test); the variable exhibiting greater association to non-adherence namely lower p-value was selected for inclusion in the final ordinal logistic regression model. Ordinal logistic regression was used for multivariate analysis. Odds ratios (ORs), 95% confidence intervals and p-values were calculated.

Results

A total of 290 Type 2 diabetes mellitus participants were recruited into the study. The mean age of the participants was 56.6 (SD ± 11.86) years. The mean duration of diabetes mellitus since diagnosis was 8 (SD ± 7.8) years.Socio-demographic characteristics of the participants are summarized in Table 1. The clinical profile of the study participants is presented in Table 2. Self-reported adherence to medication measured by MMAS-8 scale was low for 28.3 % (95% CI: 23.1, 33.5), medium for 26.2% (95% CI: 21.1, 31.3) and high for 45.5% (95% CI: 39.6, 51.3)of the study participants. Glycaemic control was good (HbA1c < 7%) for 107 (36.9%) and poor (HbA1c > 7%) for 183 (63.1%) of the study participants. A significant association was found between medication adherence and glycaemic control. 56.1% of participants in the high adherence category had good control compared to 24.3% and 19.6% of participants in the low and medium adherence category respectively (Table 3). Results of bivariate analysis between medication non-adherence and various independent variables are summarised in Table 4 and Table 5. Significant collinearity was observed between patient satisfaction with family members support and family members' attitude towards patient's illness and also between patient satisfaction with attending clinician and patient's overall experience at the clinic. Patient's satisfaction with family member support in regard to diabetes mellitus was selected in the first case and patient's satisfaction with attending clinician in the latter for inclusion in the final model (Table 6). Five factors emerged significantly associated with poor medication adherence in multivariate analysis; patients with duration disease between 2-10 years (OR = 2.07, CI = 1.01-4.22),ever being admitted for diabetes mellitus(OR = 2.94, CI = 1.60-5.41), dissatisfaction with family members support in regard to diabetes mellitus management (OR = 2.99, CI = 1.12-7.98), presence of a challenge to drug access(OR = 1.76, CI = 1.01-3.05) and satisfaction with attending clinician (OR = 3.58, CI = 1.36 - 9.43).
Table 1

Participants’ socio-demographic characteristics

CharacteristicParticipants [N, (%)]
Age(years), Mean (S.D.)= 56.6 (11.86)
Sex
Male94,(32.4)
Female196,(67.6)
Marital status
Single31,(10.7)
Married222,(76.6)
Divorced14,(4.8)
Widower/Widow23,(7.9)
Education Level
No formal education49,(16.9)
Primary85,(29.3)
Secondary104,(35.9)
Higher/university52,(17.9)
Occupation
Unemployed114,(39.3)
Civil servant60,(20.7)
Farmer33,(11.4)
Small scale business62,(21.4)
Casual laborer15,(5.2)
Other6,(2.1)
Religion
Christian283,(97.6)
Muslim6,(2.1)
Alcohol consumption
Yes12,(4.2)
No276,(95.8)
Smoking habits
Yes5,(1.7)
Never231,(79.7)
Used to but stopped54,(18.6)
Table 2

Participants’ clinical profiles

CharacteristicParticipants [N, (%)]
Body Mass Index ( kg/m2 ), Mean (S.D.)= 30.03 (7.04)
Normal60,(21)
Overweight107,(37.4)
Obese119,(41.6)
Glycosylated Hemoglobin(HBA1C), Mean (S.D.)= 7.9 (1.97)
Good (< 7%)107,(36.9)
Poor (>7%)183,(63.1)
Duration of Disease(years), Mean (S.D.) =8 (7.82)
< 266,(22.8)
2 – 10141,(48.6)
11+83,(28.6)
Delay in medication start following diagnosis (years), Mean (S.D.)= 0.5 (1.76)
Yes38,(13.1)
No252,(86.9)
Type of medication
Oral Glucose Lowering Agents(OGLA)129,(44.5)
Insulin44,(15.2)
Combination therapy (Insulin + OGLA)117,(40.3)
Number of diabetes medications
1110,(37.9)
2149,(51.4)
329,(10)
4 +2,(0.7)
Number of diabetes –related admissions
0183,(63.1)
171,(26.2)
215,(5.2)
39,(3.1)
42,(0.7)
5+5,(1.7)
Presence of diabetes complications
Yes139,(47.9)
No151,(52.1)
Presence of co-morbid states
Yes217,(74.8)
No73,(25.2)
Table 3

Relationship between Morisky Medication Adherence Scale (MMAS-8) categories and glycaemic control

Glycaemic controlLow AdherenceMedium AdherenceHigh AdherenceTotal
Good (HBA1C ≤ 7%) 26, (24.3%)21, (19.6%)60, (56.1%)107, (100%)
Poor (HBA1C >7%) 56, (30.6%)55, (30.1%)72, (39.3%)183, (100%)
Total 82, (28.3%)76, (26.2%)132, (45.5%)

Χ2 =7.902 ,p-value= 0.019

Table 4

Relationships between patient related factors and non-adherence

CharacteristicTotalLow-Medium Adherence [N, (%)]p-value
Age 0.715
18 -5412268,(55.7)
55+16890,(53.6)
Sex 0.760
Male9450,(53.2)
Female196108,(55.1)
Marital status 0.168
Married222116,(52.3)
Not married6842,(61.8)
Education level 0.236
None or Primary13468,(50.7)
Secondary or Tertiary15690,(57.7)
Occupation 0.911
Formal12266,(54.1)
Informal16892,(54.8)
Alcohol consumption 0.145
No276148,(53.6)
Yes129,(75.0)
Smoking habits 0.357
Ever smoked5929,(49.2)
Never Smoked231129,(55.8)
Satisfaction with family support? 0.024
Satisfied254132,(52.0)
Dissatisfied3324,(72.7)
Attitude of family members in regard to patient’s illness 0.03
Positive243126,(51.9)
Negative4330,(69.8)
Do Home Blood Sugar monitoring (HBSM)? 0.506
Yes12766,(52.0)
No16190,(55.9)
Table 5

Relationships between diabetes treatment factors and non-adherence

VariableTotalLow-Medium Adherence [N, (%)]p-value
Injection/insulin medication 0.049
No12962,(48.1)
Yes16196,(59.6)
Duration of Disease 0.004
< 2 year6625,(37.9)
2 – 10 years14188,(62.4)
11+8345,(54.2)
Number of Diabetes Medications 0.052
111052,(47.3)
214984,(56.4)
3+3122,(71.0)
Delay in medication start following diagnosis? 0.011
No252130,(51.6)
Yes3828,(73.7)
Ever DM related admission? 0.004
No18388,(48.1)
Yes10770,(65.4)
Presence of complication or comorbidity? 0.193
No4219,(45.2)
Yes248139,(56.0)
Frequency of DM clinic 0.664
3 monthly or less16792,(55.1)
4 monthly or more12063,(52.5)
Attendance of diabetes education session 0.739
No147,(50.0)
Yes275150,(54.5)
Challenge in drug access? 0.069
No14185,(60.3)
Yes12662,(49.2)
Satisfaction with attending clinician? 0.096
Satisfied258136,(52.7)
Dissatisfied2920,(69.0)
Overall clinic experience 0.104
Poor1810,(55.6)
Average7533,(44.0)
Good190111,(58.4)
Table 6

Logistic regression analysis of factors associated with poor medication adherence

VariableOR95%CIp-value
Injection/insulin medication
No1
Yes1.460.80-2.680.216
Duration of Disease
< 2 year1
2 – 10 years2.071.01-4.220.047
11+0.990.43-2.280.983
Number of Diabetes Medications
11
21.160.63-2.120.631
3+2.260.80-6.410.125
Ever DM related admission?
No1
Yes2.941.60-5.41<0.0001
Satisfaction with family support?
Satisfied1
Dissatisfied2.991.12-7.980.029
Presence of complication or comorbidity?
No1
Yes1.850.84-4.060.125
Satisfaction with attending clinician?
Satisfied1
Dissatisfied3.581.36-9.430.01
Alcohol consumption
No1
Yes0.220.05-1.050.057
Delay in medication start following diagnosis?
No1
Yes2.280.96-5.390.061
Marital status
Married1
Not married1.200.60-2.370.609
Challenge in drug access?
No1
Yes1.761.01-3.050.046
Participants’ socio-demographic characteristics Participants’ clinical profiles Relationship between Morisky Medication Adherence Scale (MMAS-8) categories and glycaemic control Χ2 =7.902 ,p-value= 0.019 Relationships between patient related factors and non-adherence Relationships between diabetes treatment factors and non-adherence Logistic regression analysis of factors associated with poor medication adherence

Discussion

This study found less than one in every two patients (45.5%) was fully adhering to the prescribed medications. This proportion of medication adherence is comparable to other studies done among Type 2 diabetic patients in clinic settings done in Kenya and in the Eastern Africa region [20-22]. This is a worrying trend given that the incidence of diabetes in Kenya and Africa is rising [8]. National health systems are poorly coping with the increasing burden of non-communicable diseases owing to underdeveloped public health systems and inadequate funding [23]. According to the WHO; increasing effectiveness of adherence interventions may have greater impact on the health of populations than improvements in specific medical treatments [3]. This is because however efficacious novel treatments are, when patients do not take them correctly, then the expected benefits such as averted morbidity, disability and mortality may not be realised. Indeed among Type 2 diabetic patients; a study demonstrated that all-cause hospitalisation increased by 58% and all-cause mortality increased by 81% among diabetic patients who were poorly adhering to their medications [24]. Medication non-adherence is preventable and there is great need to support patients adhere to their prescriptions. According the 2010 Ministry of Health (MOH) clinical guidelines for the management of diabetes mellitus; good control is indicated by a glycosylated hemoglobin level of less than 7% [25]. In this study one hundred and seven (36.9%) of the patients who participated in the study achieved this cut-off of blood sugar control. Studies done in Kenya and other parts of Africa have shown low levels of glycemic control ranging from 17%-38% [20, 26,27]. Chronically raised blood sugar and associated metabolic disturbances related to insufficiency in insulin production or/and insulin action is the underlying pathology in diabetes mellitus. Glycemic control is hence the ultimate objective of any diabetes mellitus therapy. Good glycaemic control among type 2 diabetes mellitus patients involves interplay of self-management measures including physical activity and diet in addition to medication adherence [3]. This can explain the discrepancy between the better medication adherence scores and poorer glycemic control outcome in this study population. Importantly these low levels of glycaemic control in Kenya and Africa in contribute to high rates of diabetes related morbidity and mortality. Globally diabetes is a leading cause of blindness, kidney failure, heart attacks, stroke and lower limb amputation [28]. This study found a significant inverse relationship between high adherence scores and lower assayed values of glycosylated haemoglobin (HbA1C). The patients with high scores in the MMAS-8 reflecting good medication adherence were also most likely to have lower and optimal glycosylated haemoglobin values. Other workers in African contexts have also demonstrated this effect [20, 21]. This finding demonstrates that medication adherence plays an important role in maintaining blood sugar levels within normal ranges. Furthermore it supports the use of quick to administer and self-reported medication adherence scales such as the MMAS-8 in busy clinical practices as a means of quickly filtering patients who are poorly adhering to medication for intensified counselling to reinforce medication adherence. Amongst factors that fuel medication non-adherence; dissatisfaction with close family members' support in regard to diabetes mellitus management emerged significantly associated with non-adherence. Poor social support has been shown in several studies to be associated with inadequate management of diabetes mellitus [27]. Most patients enrolled in this study reported that the family members played the role of encouraging and reminding them of their medication, this is important for patients suffering chronic illnesses who tend to feel isolated in their daily struggle to contain their disease. The role of a treatment supporter usually a close family member in diabetes mellitus management has often been neglected; this is in contrast with care provision for chronic communicable illness such as HIV/AIDS and tuberculosis (TB) that have long periods of medication use [29, 30]. In these two conditions patients' registration into care usually involves engaging the patient in identification of a suitable treatment supporter. The identified treatment supporter is informed of the patient's diagnosis, educated on the healthy lifestyle modifications, importance of medication adherence and clinic attendance in order that he/she may encourage the patient towards these goals. Age was not found to be significantly associated with non-adherence in this study. Whereas it has been shown that the prevalence of diabetes mellitus increases with age in Kenya [31]; medication adherence however has been shown either not be affected by the patient's age [20] or actually improve with age [32]. The majority of participants in this study was over fifty-five years of age and would likely be living with children or relatives; the protective effect of family noted above is likely to facilitate adherence with medication. In contrast younger patients who are professionally active have been shown to be more likely skip or forget their medication [33]; hence poorer adherence. Sex was also found not to be significantly associated with adherence in this study. Some studies have found that females were more likely not to adhere to medications [34, 35]. Due to the relative minority of males (32.4%) in the clinic attendance, we may have been unable to demonstrate this association. Level of education in this study was found not to be significantly associated with medication adherence. Several studies have also shown similar findings [36, 37]. The crucial aspect as regards to medication adherence as demonstrated in qualitative studies is whether a patient understands their prescribed medication [38]. This lays great importance on patient education and counseling at diagnosis and during follow-up in simple language within the patient's level of understanding. Alcohol usage has been show in other studies to be associated with medication non-adherence [39], however due to the small number of alcohol users in this study we may have been unable to demonstrate this association. Home blood sugar monitoring (HBSM) is an important part of diabetes self-management and provides the patient with an ongoing feedback on effectiveness of his/her diabetes management efforts i.e. whether blood sugar levels are within target ranges. However in our study; there was no association between the HBSM and medication adherence. This finding is consistent with findings from another study conducted in western Kenya that demonstrated low levels of blood glucose monitoring and no association with glycemic control [40]. In this study, this finding can be explained by a majority of patients lacking personal glucometers thus not practicing HBSM and for those who have glucometers not adjusting their medication based on blood sugar values obtained. In this study; ever having been admitted for diabetes mellitus was shown to be significantly associated with of non-adherence. Physiologically poor adherence is associated with uncontrolled blood sugar levels that result in accelerated end organ damage [2]. Frequent admissions have economic impacts at the personal level and public health level. At the personal level costs accrue from direct loss in productivity and income. Cost of treatment has been implicated as a barrier in achieving medication adherence and glycemic control among Type 2 diabetes mellitus patients [41]. Almost half of diabetic patients recruited reported cost as their main challenge to medication access. In Kenya, where the bulk of health care costs are paid out of pocket (OOP); this increased expenditure can result in catastrophic impoverisation of individuals and their families especially if the breadwinner is affected [42]. At the public or national health level; increased resources need to be invested in caring for these patients including health personnel; medications and physical facilities. The estimated annual cost of diabetes in the sub-Saharan Africa region has been estimated at over 8000 United States dollars per patient [23]. Patients who have had diabetes for a period of 2 to 10 years were found in this study to have less adherence to the diabetes mellitus medication than newly diagnosed patients(duration of disease <2 years). This finding could be associated with the progressive Beta-cell failure in diabetes mellitus which results in progressive increase in the number and dosage of medications required to achieve optimal glycaemic control. Regimen complexity is also associated with an increase in medication side effects which limits the willingness of patients to take their medicines. Longer time periods between clinic appointments for these experienced patients has also been shown to contribute to poor medication adherence [34]. Disease and treatment factors such as number of diabetes mellitus medication, presence of injectable medication and presence of comorbidities and complications were on bivariate analysis significantly associated with poor adherence. However the significance in association was lost when they were placed in multivariate analysis. This could have been due to association of these factors with other factors associated with medication adherence that when controlled for were able cater for their confounding effects. These findings suggest that these factors do not predict medication adherence behaviour in this cohort of patients. Attendance of health education sessions was not significantly associated with good medication adherence. Furthermore majority of the patients had not been taught how to adjust medication based on blood sugar readings. This finding differs from a similar study conducted in Uganda which demonstrated that ever attending a health education session lowered the odds of non-adherence [37]. Whereas the classroom or group approach utilised at the clinic is effective when many patients need to be educated; the information disseminated is generalised and may not satisfy the individual needs of each patient. It has been shown that diabetic patients consider obtaining information regarding their prescribed medication as their foremost need towards medication adherence [38]. Supplementary personalised counselling and education sessions targeted at uncovering the particular adherence barriers pertaining to each patient would be of great value. Indeed studies have shown that patients receiving care from specialists who are typically busy and have less time per individual patient are less likely to adhere to their medication [33, 35]. Similarly in this study, nurses were reported to be the commonest source of diabetes health information and not the attending doctors. Satisfaction with the attending clinician emerged as a significant contributor to good medication adherence. Patients who were dissatisfied in their clinician were three times more likely to be non-adherent to their diabetic medication compared to those who were. In a similar study, patients reporting poor patient-provider communication and dismissing attachment were significantly less likely to adhere to their medication and consequently had poorer glycaemic control [43]. General dissatisfaction with the quality of health services provided at a health facility is also a recognised barrier to medication adherence in patients who received care there [20]. Dissatisfied patients are also less likely to attend follow-up clinics or attend education sessions and have little trust in the medication prescribed.

Conclusion

In conclusion, a majority of type 2 diabetes mellitus patients have suboptimal medication adherence which is associated with poor blood sugar control. Family support, affordability of medications and good healthcare provider- patient communication are important factors in ensuring medication adherence. This study recommends that hospital management boards implement facilitated participation of family members in the diabetic patient care process, a scheme for free or subsidised medication provision as well as health provider communication trainings as foundational steps in improving medication adherence among Type 2 DM patients. Adherence to medication is a common problem globally for patients with chronic illnesses including Type 2 DM; Medication non-adherence is associated with poor glycemic control and thus worse clinical outcomes. Medication adherence pattern of a typical Kenyan population of Type 2 DM patients; The factors that drive medication non-adherence among Type 2 DM patients in Kenya, which could inform health managers in designing effective medication adherence strategies.

Competing interests

Authors declare no competing interests.
  33 in total

1.  Detecting alcoholism. The CAGE questionnaire.

Authors:  J A Ewing
Journal:  JAMA       Date:  1984-10-12       Impact factor: 56.272

2.  The patient-provider relationship: attachment theory and adherence to treatment in diabetes.

Authors:  P S Ciechanowski; W J Katon; J E Russo; E A Walker
Journal:  Am J Psychiatry       Date:  2001-01       Impact factor: 18.112

3.  Patients' adherence to diabetes treatment.

Authors:  R Shobhana; R Begum; C Snehalatha; V Vijay; A Ramachandran
Journal:  J Assoc Physicians India       Date:  1999-12

4.  Effect of medication nonadherence on hospitalization and mortality among patients with diabetes mellitus.

Authors:  P Michael Ho; John S Rumsfeld; Frederick A Masoudi; David L McClure; Mary E Plomondon; John F Steiner; David J Magid
Journal:  Arch Intern Med       Date:  2006-09-25

5.  Alcohol consumption is inversely associated with adherence to diabetes self-care behaviours.

Authors:  A T Ahmed; A J Karter; J Liu
Journal:  Diabet Med       Date:  2006-07       Impact factor: 4.359

6.  Cardiovascular risk factors in patients with type 2 diabetes mellitus in Kenya: levels of control attained at the Outpatient Diabetic Clinic of Kenyatta National Hospital, Nairobi.

Authors:  C F Otieno; V Vaghela; F W Mwendwa; J K Kayima; E N Ogola
Journal:  East Afr Med J       Date:  2005-12

7.  New medication adherence scale versus pharmacy fill rates in seniors with hypertension.

Authors:  Marie Krousel-Wood; Tareq Islam; Larry S Webber; Richard N Re; Donald E Morisky; Paul Muntner
Journal:  Am J Manag Care       Date:  2009-01       Impact factor: 2.229

8.  Factors associated with poor glycemic control among patients with type 2 diabetes.

Authors:  Maysaa Khattab; Yousef S Khader; Abdelkarim Al-Khawaldeh; Kamel Ajlouni
Journal:  J Diabetes Complications       Date:  2009-03-17       Impact factor: 2.852

9.  Non-adherence to diabetes treatment at Mulago Hospital in Uganda: prevalence and associated factors.

Authors:  Joan N Kalyango; Erisa Owino; Agatha P Nambuya
Journal:  Afr Health Sci       Date:  2008-06       Impact factor: 0.927

10.  Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: a randomized prospective 6-year study.

Authors:  Y Ohkubo; H Kishikawa; E Araki; T Miyata; S Isami; S Motoyoshi; Y Kojima; N Furuyoshi; M Shichiri
Journal:  Diabetes Res Clin Pract       Date:  1995-05       Impact factor: 5.602

View more
  19 in total

1.  Medication Non-Adherence and Associated Factors Among Diabetic Patients Visiting General Hospitals in the Eastern Zone of Tigrai, Northern Ethiopia.

Authors:  Ephrem Mebrahtu Araya; Haylay Araya Gebrezgabiher; Gebretsadkan Hintsa Tekulu; Niguse Meles Alema; Desalegn Getnet; Hirut Teame Gebru; Betelhem Anteneh Adamu
Journal:  Patient Prefer Adherence       Date:  2020-10-29       Impact factor: 2.711

2.  Glycaemic control among type 2 diabetes patients in sub-Saharan Africa from 2012 to 2022: a systematic review and meta-analysis.

Authors:  Jean-Pierre Fina Lubaki; Olufemi Babatunde Omole; Joel Msafiri Francis
Journal:  Diabetol Metab Syndr       Date:  2022-09-20       Impact factor: 5.395

3.  Factors related to barriers and medication adherence in patients with type 2 diabetes mellitus: a cross-sectional study.

Authors:  Elida Zairina; Gesnita Nugraheni; Arie Sulistyarini; Catur Dian Setiawan; Sunil Kripalani; Safira Indah Lestari
Journal:  J Diabetes Metab Disord       Date:  2022-01-29

4.  Adherence to Medication, Diet and Physical Activity and the Associated Factors Amongst Patients with Type 2 Diabetes.

Authors:  Alireza Mirahmadizadeh; Haniyeh Khorshidsavar; Mozhgan Seif; Mohammad Hossein Sharifi
Journal:  Diabetes Ther       Date:  2020-01-08       Impact factor: 2.945

5.  Factors associated with stroke survivors' inconsistent uptake of physiotherapy interventions at Turton Community Health Centre, KwaZulu-Natal.

Authors:  Ntombifuthi Mlambo; Khumbulani Hlongwana
Journal:  S Afr J Physiother       Date:  2020-10-07

6.  Glycemic Control of Diabetes Mellitus Patients in Referral Hospitals of Amhara Region, Ethiopia: A Cross-Sectional Study.

Authors:  Berhanu Elfu Feleke; Teferi Elfu Feleke; Melkamu Beyene Kassahun; Wondemu Gebrekirose Adane; Netsanet Fentahun; Abel Girma; Alamirew Alebachew; Eyaya Misgan; Hanna Demelash Desyibelew; Mulat Tirfie Bayih; Omer Seid
Journal:  Biomed Res Int       Date:  2021-01-16       Impact factor: 3.411

Review 7.  Determinants of Non-Adherence to Treatment Among Patients with Type 2 Diabetes in Kenya: A Systematic Review.

Authors:  Brian Barasa Masaba; Rose M Mmusi-Phetoe
Journal:  J Multidiscip Healthc       Date:  2021-01-05

8.  Health Inequalities Among Elderly Type 2 Diabetes Mellitus Patients in Japan.

Authors:  Peng Jiang; Akira Babazono; Takako Fujita
Journal:  Popul Health Manag       Date:  2019-10-29       Impact factor: 2.459

Review 9.  Review of Ongoing Activities and Challenges to Improve the Care of Patients With Type 2 Diabetes Across Africa and the Implications for the Future.

Authors:  Brian Godman; Debashis Basu; Yogan Pillay; Julius C Mwita; Godfrey Mutashambara Rwegerera; Bene D Anand Paramadhas; Celda Tiroyakgosi; Patrick Mbah Okwen; Loveline Lum Niba; Justice Nonvignon; Israel Sefah; Margaret Oluka; Anastasia N Guantai; Dan Kibuule; Francis Kalemeera; Mwangana Mubita; Joseph Fadare; Olayinka O Ogunleye; Larry A Distiller; Enos M Rampamba; Jeffrey Wing; Debjani Mueller; Abubakr Alfadl; Adefolarin A Amu; Zinhle Matsebula; Aubrey Kalungia; Trust Zaranyika; Nyasha Masuka; Janney Wale; Ruaraidh Hill; Amanj Kurdi; Angela Timoney; Stephen Campbell; Johanna C Meyer
Journal:  Front Pharmacol       Date:  2020-03-20       Impact factor: 5.810

10.  Satisfaction and experiences of patients taking fingolimod and involved in a pharmacy-based patient support program in Switzerland - a qualitative study.

Authors:  Aline Bourdin; Julie Dubois; Rose-Anna Foley; Myriam Schluep; Olivier Bugnon; Jérôme Berger
Journal:  BMC Health Serv Res       Date:  2020-05-14       Impact factor: 2.655

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.